Linifanib (ABT 869) is an oral tyrosine kinase inhibitor with antineoplasic activity. As a dual inhibitor, Linifanib, is being tested on several different cancers.
Haddley, K., et al.: Drugs of the Future, 35, 106 (2010), Cheng, A., et al.: J. Med. Chem., 53, 4502 (2010),